Table 1.
Overview of CAR-NK studies to date using cell lines
| # | Reference: first author (journal, year) | Effector cell | Vehicle | Target | generation | Activation signal | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retro | lenti | mRNA | plasmid | transposon | 1 | 2 | 3 | |||||
| 1 | Uherek (Blood 2002) | NK-92 | x | HER2 | x | CD3ζ | ||||||
| 2 | Schirrmann (Cancer Gene Ther 2002) | YTS | x | CEA | x | CD3ζ | ||||||
| 3 | Daldrup-Link (Eur Radiol 2005) | NK-92 | x | x | HER2 | x | CD3ζ | |||||
| 4 | Schirrmann (Leukemia Research 2005) | YT | x | CD33 | x | CD3ζ | ||||||
| 5 | Meier (Nucl Med Biol 2008) | NK-92 | x | HER2 | x | CD3ζ | ||||||
| 6 | Muller (Cancer Immunol Immunother 2008) | NK-92 | x | CD20 | x | murine CD3ζ | ||||||
| 7 | Tavri (Mol Imaging 2009) | NK-92 | x | EpCAM | x | CD3ζ | ||||||
| 8 | Boissel (Leukemia Res 2009) | NK-92 | x | x | CD19 | x | CD3ζ | |||||
| 9 | Meier (Magn Reson Med 2011) | NK-92 | x | EpCAM | x | CD3ζ | ||||||
| 10 | Sahm (Cancer Immunol Immunother 2012) | NK-92, NKL | 2 | EpCAM | x | CD28-CD3ζ | ||||||
| 11 | Boissel (Leukemia Lymphoma 2012) | NK-92 | x | x | CD19, CD20 | x | CD3ζ | |||||
| 12 | Esser (J Cell Mol Med 2012) | NK-92 | x | GD2 | x | CD3ζ | ||||||
| 13 | Tassev (Cancer Gene Ther 2012) | NK-92-MI | x | EBNA | x | CD3ζ | ||||||
| 14 | Alkins (Cancer Res 2013) | NK-92 | x | HER2 | x | CD3ζ | ||||||
| 15 | Boissel (OncoImmunol 2014) | NK-92 | x | CD19, CD20 | x | CD3ζ | ||||||
| 16 | Jiang (Mol Oncol 2014) | NK-92-MI | 3 | CD138 | x | CD3ζ | ||||||
| 17 | Chu (Leukemia 2014) | NK-92 | 2 | CS1 | x | CD28-CD3ζ | ||||||
| 18 | Seidel (Cancer Immunol Immunother 2015) | NK-92 | x | GD2 | x | CD3ζ | ||||||
| 19 | Schönfeld (Mol Ther 2015) | NK-92 | 2 | HER2 | x | x | CD28-CD3ζ/CD137-CD3ζ/CD3ζ | |||||
| 20 | Han (Sci Reports 2015) | NK-92, NKL | 2 | EGFR | x | CD28-CD3ζ | ||||||
| 21 | Clémenceau (J Immunol Res 2015) | NK-92 | x | Her2 | x | FceRIγ | ||||||
| 22 | Liu (Oncol Reports 2015) | NK-92 | x | HER2 | x | CD28-CD3ζ | ||||||
| 23 | Zhao (Leukemia 2015) | NK-92-MI | x | WT-1 | x | CD137-CD3ζ | ||||||
| 24 | Muller (J Immunother 2015) | YTS | 2 | EGFRvIII | x | DAP12 | ||||||
| 25 | Alkins (Neuro-Oncol 2016) | NK-92 | x | HER2 | x | CD3ζ | ||||||
| 26 | Genßler et al. (OncoImmunol 2016) | NK-92 | 2 | EGFRvIII | x | CD28-CD3ζ | ||||||
| 27 | Zhang (J Natl Cancer Inst 2016) | NK-92 | 2 | HER2 | x | CD28-CD3ζ | ||||||
| 28 | Romanski (J Cell Mol Med 2016) | NK-92 | x | CD19 | x | CD3ζ | ||||||
| 29 | Topfer (J Immunother 2016) | YTS | 2 | EGFRvIII | x | DAP12 | ||||||
| 30 | Chen (Oncotarget 2016) | NK-92, PB-NK | 2 | EGFR | x | CD28-CD3ζ | ||||||
| 31 | Siegler (Mol Ther 2017) | NK-92 | x | x | CD19, HER2 | x | x | CD28-CD137-CD3ζ/CD28-CD3ζ | ||||
| 32 | Oelsner (Cytotherapy 2017) | NK-92 | 2 | CD19 | x | x | CD28-CD3ζ/CD137-CD3ζ/CD3ζ | |||||
| 33 | Chen (Oncotarget 2017) | NK-92 | 2 | CD3 | x | CD137-CD28-CD3ζ | ||||||
| 34 | Chen (Leukemia 2017) | NK-92 | 2 | CD5 | x | CD137-CD28-CD3ζ | ||||||
| 35 | Li (Cell Stem Cell 2018) | NK-92, iPSC | x | mesothelin | x | x | x | 2B4-CD3ζ/CD28-CD137-CD3ζ/DAP10-CD3ζ/CD137-CD3ζ/2B4-DAP12-CD3ζ/2B4-DAP10-CD3ζ/CD137-2B4-CD3ζ/CD3ζ | ||||
| 36 | Zhao (Eur J Inflamm 2018) | NK-92-MI | x | CD19, CD138 | x | CD28-CD3ζ | ||||||
| 37 | Murakami (Anticancer Res 2018) | KHYG-1 | x | EGFRvIII | x | CD137-CD3ζ | ||||||
| 38 | Zhang (J Immunol Res 2018) | NK-92 | 2 | EpCAM | x | CD137-CD3ζ | ||||||
| 39 | Yu (Mol Therapy 2018) | NK-92 | x | GPC3 | x | CD28-CD3ζ | ||||||
| 40 | Nowakowska (Cancer Immunol Immunother 2018) | NK-92 | 2 | HER2 | x | x | CD28-CD3ζ/CD137-CD3ζ/CD3ζ | |||||
| 41 | Tang (Am J Cancer Res 2018) | NK-92-MI | 3 | CD33 | x | x | CD28-CD137-CD3ζ | |||||
| 42 | Schnalzger (EMBO J 2019) | NK-92 | 2 | HER2 | x | CD28-CD3ζ | ||||||
| 43 | Ao (J Immunother 2019) | NK-92 | x | AlphaFR | x | x | x | CD3ζ/CD28-CD3ζ/CD28-CD137-CD3ζ | ||||
| 44 | Kloess (Human Gene Therapy 2019) | NK-92, PB | x | CD123 | x | CD28-CD137-CD3ζ | ||||||
| 45 | Kim (Biomaterials 2019) | NK-92-MI | x | EGFR | x | CD28-CD3ζ | ||||||
| 46 | Xu (J Hematol Oncol 2019) | NK-92 | 3 | CD5 | x | 2B4-CD3ζ/CD137-CD3ζ | ||||||
| 47 | Batchu (Surgery 2019) | NK-92-MI | x | x | mesothelin | x | CD28-CD137-CD3ζ | |||||
| 48 | Kulemzin (BMC Med Genom 2019) | NK-92, YT | 2 | PMSA | x | CD28-CD3ζ | ||||||
| 49 | You (Am J Cancer Res. 2019) | NK-92-MI | x | CD7 | x | CD28-4-1BB-CD3ζ | ||||||
| 50 | Oelsner (Int J Cancer 2019) | NK-92 | 2 | FLT3 | x | CD28-CD3ζ | ||||||
| 51 | Parlar (Eur J Immunol 2019) | NK-92, YTS | x | CD3 δγεδ, TCR | x | CD3ζ | ||||||
| 52 | Mensali (EBioMed 2019) | NK-92 | x | CD3 δγεδ, TCR | x | CD3ζ | ||||||
| 53 | Ravi (Leukemia 2020) | NK-92 | x | CD19 | x | CD3ζ | ||||||
| 54 | Hu (Sci Report 2020) | NK-92-MI | x | Tissue factor | x | CD137-CD3ζ | ||||||
| 55 | Huang (Cancer Manag Res 2020) | NK-92 | x | GPC3 | x | x | x | CD3ζ/CD28-CD3ζ/2B4-CD3ζ/DNAM1-CD3ζ/DNAM1-2B4-CD3ζ | ||||
| 56 | Mitwasi (Sci Report 2020) | NK-92-MI | x | GD2 | x | CD28-CD3ζ | ||||||
| 57 | Hambach (Cells 2020) | NK-92 | x | CD38 | x | CD28-CD137-CD3ζ | ||||||
| 58 | Cao (Biochem Biophys Res Commun 2020) | NK-92 | 2 | Mesothelin, CD19 | x | CD28-CD137-CD3ζ | ||||||
| 59 | Li (J Cancer Res Ther 2020) | NK-92 | x | Robo1 | x | CD137-CD3ζ | ||||||
| 60 | Montagner (Cells 2020) | NK-92 | x | PMSA | x | CD28-CD3ζ | ||||||
| 61 | Nakazawa (Anticancer Res 2020) | KHYG-1 | x | EGFRvIII | x | CD137-CD3ζ | ||||||
| 62 | Robbins (eLife 2020) | NK-92 | – | – | – | – | – | PDL1 | x | FcεR1γ | ||
| 63 | Lee (J Control Release 2020) | NK-92 | x | Fra, TRAIL | x | CD27-CD3ζ | ||||||
| 64 | Liu (Cytotherapy 2020) | NK-92 MI | 3 | CD19 | x | CD137-CD3ζ | ||||||
| 65 | Yang (Front Pharmacol 2020) | NK-92 MI | 2 | B7H3 | x | CD137-CD3ζ | ||||||
| 66 | Jamali (Front immunol 2020) | NK-92, NKL, PB | 3 | CD19 | x | CD137-CD3ζ | ||||||
| 67 | Ahn (Biomaterials 2020) | NK-92 | – | – | – | – | – | EGFR | x | CD28-DAP10-CD3ζ | ||
| 68 | Fabian (J Immunother Cancer 2020) | haNK-92 | – | – | – | – | – | PD-L1 | – | – | – | – |
| 69 | Gurney (Haematologica 2020) | KHYG-1, PB-NK | x | CD38 | x | CD28-CD3ζ | ||||||
| 70 | Tseng (Nat Commun 2020) | NK-92MI, PB-NK | x | 2 | CD147, GPC3 | x | CD28-CD137-CD3ζ | |||||
| 71 | Eitler (Journal for ImmunoTherapy of Cancer 2021) | NK-92 | 2 | HER2 | x | CD28-CD3ζ | ||||||
| 72 | Kang (Int J Mol Sci 2021) | NK-92MI, KHYG-1 | 3 | CD19 | CD28-CD3ζ | |||||||
Numbers in the "Vehicle" column refer to the generation of retro- and lentiviruses. – denotes information not provided in the study. Other abbreviations: gen. = CAR generation. Lenti lentivirus, Retro retrovirus, Transp transposon
There is an interactive and extended version of this table available online, also providing regular updates: http://www.carnkreview.com